drugset / Trial / NCT00005018

Safety and Effectiveness of a Combination Anti-HIV Drug Treatment

NCT00005018

Phase 4 Completed 150 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).

Timeline

Start
1999-07
Primary completion
Completion
2000-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 300 mg
Subject Didanosine Small molecule 400 mg
Subject Efavirenz Other / unclassified 600 mg
Subject Hydroxyurea Other / unclassified 500 mg